Osteoarthritis
Conditions
Interventions
A group:Rivaroxaban (5 mg po qd)
B group:Rivaroxaban (10 mg po qd)
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Primary unilateral total knee arthroplasty; 2. Aged 40-76 years male and female; 3. Patient should agree to joint the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patient who use aspirin for tertiary prevention or double antiplatelet therapy, including acute coronary syndrome in past 3 months, post-operation of PCI or cardiac valve replacement, and other high-risk patient; 2. Patient with high risk of VTE, including previous VTE history, malignant tumor, hypercoagulable state, other known states that easily lead to thrombosis and undergoing anticoagulation; 3. Patient with other severe disease in heart, brain, lung, kidney or blood; 4. Patient with coagulation dysfunction, trend of hemorrhage or has active hemorrhage before operation; 5. Patient with systematic artery stenosis or received stent implantation for such disease; 6. Patient with Severe renal insufficiency(Ccr 30).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ultrasound of deep vein of lower extremity;post-operation symptomatic venous thromboembolism (VTE) event;bleeding event;total blood loss;poor healing of incisions; | — |
Secondary
| Measure | Time frame |
|---|---|
| traditional Coagulation Indicators;the incidence of subcutaneous ecchymosis;amount of blood transfusion; | — |
Countries
China
Contacts
Public ContactShirong Chen
The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed